Evidence map›Paper›PMID 40601000›Full record

ReviewPathologie (Heidelberg, Germany)2025

[Current grading of prostate cancer. German version].

Yosamin Gonzalez Belisario, Geert J L H van Leenders

Abstract readEnglish AbstractReview
In one paragraph

Review in Pathologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yosamin Gonzalez BelisarioAbteilung für Pathologie, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, Niederlande.
Geert J L H van LeendersAbteilung für Pathologie, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, Niederlande. g.vanleenders@erasmusmc.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Gleason grading system is the cornerstone of risk stratification and clinical decision-making in prostate cancer patients. In the last decade, new insights on quantitative grading and the importance of particular growth patterns have further optimized pathological tumor grading. This review provides an update on the latest grading recommendations and discusses contemporary research directions.

Indexed as

Neoplasm GradingProstatic NeoplasmsGermanyHumansMaleClassification systemCribriform patternGleason scoreGrowth patternIntraductal carcinoma

Identifiers

PMID40601000
PMCPMC12373671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.